| US 7,524,843 B2 | ||
| Fab I inhibitors | ||
| William H. Miller, Collegeville, Pa. (US); Kenneth A. Newlander, West Chester, Pa. (US); Mark A. Seefeld, Collegeville, Pa. (US); Irene N. Uzinskas, Villanova, Pa. (US); Walter E. Dewolf, Jr., Glenmoore, Pa. (US); and Dalia R. Jakas, Norristown, Pa. (US) | ||
| Assigned to Affinium Pharmaceuticals, Inc., Ontario (Canada) | ||
| Filed on Jul. 18, 2007, as Appl. No. 11/779,578. | ||
| Application 11/779578 is a continuation of application No. 11/007927, filed on Dec. 09, 2004. | ||
| Application 11/007927 is a continuation of application No. 10/089755, granted, now 6,846,819, previously published as PCT/US00/27844, filed on Oct. 06, 2000. | ||
| Claims priority of provisional application 60/158704, filed on Oct. 08, 1999. | ||
| Prior Publication US 2008/0125423 A1, May 29, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/4375 (2006.01); C07D 265/36 (2006.01) | ||
| U.S. Cl. 514—230.5 [544/105; 544/333] | 14 Claims |
1. A compound according to formula (I):
  R1 is H or C1-4alkyl;
R2 is H, or C1-4alkyl;
R3 is
 R4 is H or C1-4alkyl;
 R5 is CH2 when the bond to which it is attached is a double bond; or R5 is H or C1-4alkyl when the bond to which it is attached is a single bond;
R6 is H or C1-4alkyl;
R7 is H, or C1-6alkyl;
each X independently is H, C1-4alkyl, CH2OH, OR′, SR′, CN, N(R′)2, CH2N(R′)2, NO2, CF3, CO2R′, CON(R′)2, COR′, NRC(O)R′, F, Cl, Br, I or —S(O)rCF3;
W is S or O;
M is CH2 or O;
L is CH2 or C(O);
E is O or NR′;
each R′ independently is H, or C1-6alkyl; and
r is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.
|